Multiple Myeloma
Conditions
Interventions
therapy group:Chidamide combined with Thalidomide, Cyclophosphamide and Dexamethasone
Sponsors
The First Affiliated Hospital of Medical College of Zhejiang University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Understand and voluntarily sign informed consent form of patients; 2. Patients with age >= 18-75 years old; 3. According to the IMWG diagnostic criteria for multiple myeloma in 2014, the patients who were diagnosed as refractory and relapsed and needed immediate rescue treatment; 4. Patients who have been treated with bortezomib and lenalidomide in the past and assessed as disease progression after the final course of treatment.
Exclusion criteria
Exclusion criteria: 1. Patients with any serious illness that can lead to an unbearable risk when participating in this study; 2. Patients with diseases that need continuous active treatment, such as unstable heart disease, stroke, rheumatoid arthritis, lupus, etc.; 3. Pregnant or lactating women; 4. Patients with a history of malignant tumor other than mm, unless the patient has no disease and survived for more than 3 years; 5. Patients who were vaccinated with live vaccine and live attenuated vaccine within 4 weeks before randomization.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall response rate;safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival;Overall survival; | — |
Countries
China
Contacts
Public ContactZhen Cai
The First Affiliated Hospital of Medical College of Zhejiang University
Outcome results
None listed